Publication details
První zkušenosti s terapií Macugenem u vlhké formy VPMD
| Title in English | First experience with Macugen therapy in wet AMD |
|---|---|
| Authors | |
| Year of publication | 2007 |
| MU Faculty or unit | |
| Citation | |
| Description | Macugen (pegaptanib) is a modified oligonucleotide that specifically binds to the extracellular VEGF165, and inactivates it. Inhibits the processes of formation and progression of subretinal neovascularization. Selective inhibition of VEGF165 does not lead unlike non selective inhibition, to damage of the physiological vascular structure of the choroid. |